Exactech Continues to Expand Spine Portfolio Through First Internally-Developed Product

Exactech Continues to Expand Spine Portfolio Through First Internally-Developed Product

Share this story with your network

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company’s Exactech Spine division has launched the Proliant™ Polyaxial Pedicle Screw System for orthopaedic and neurosurgeons. This product launch represents the first spinal system developed in-house by Exactech. The company established its spinal division with two acquisitions over the past three years.

“We are excited to bring this product to market after having achieved all of our product design objectives. The implants and instrumentation were designed to help the surgeon complete vertebral stabilization in a straight-forward manner, leaving their attention to the more complex aspects of lumbar fusion surgery.”

The Proliant Polyaxial Pedicle Screw System is designed to provide secure fixation of the thoracolumbar spine while offering surgeons improved speed and ease-of-use. The pedicle screw has a dual lead thread for faster insertion and a patented Tightlok™ thread pattern that is designed to reduce screw pull out and facilitate fusion. The low-profile screw is designed to reduce the risk of tissue impingement, and the EZ Set tulip head allows the surgeon to easily position and set the tulip head in any position for rod insertion, creating a simple, easy-to-use posterior lumbar fixation system.

Exactech Senior Vice President and Spine Division General Manager Bruce Thompson said, “We are excited to bring this product to market after having achieved all of our product design objectives. The implants and instrumentation were designed to help the surgeon complete vertebral stabilization in a straight-forward manner, leaving their attention to the more complex aspects of lumbar fusion surgery.

“The launch of this product is key for our spine division, as posterior lumbar fixation is a core sector of the growing spine market. Using the technology and innovative features developed as part of the Proliant System, Exactech will also create future line extensions to expand into other growing spine market segments,” Thompson said.

Exactech began conducting clinical evaluations of the Proliant system at the end of March 2011, and full market launch is targeted for the second half of 2011.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up athttp://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

 

Leave a Comment

Your email address will not be published. Required fields are marked *

*